The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: T-cell binding fusion peptides. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

T-cell binding fusion peptides is a key innovation area in the pharmaceutical industry

T-cell binding fusion peptides are a type of synthetic or engineered peptide that are designed to interact with T cells, a type of immune cell involved in the adaptive immune response. T-cell binding fusion peptides are composed of amino acids, just like natural proteins and peptides. They are often engineered to include sequences that mimic or resemble antigens or epitopes recognized by T cells. The design may also include additional sequences or motifs that enhance binding to TCRs. These peptides are typically created to have specific binding affinity for T-cell receptors (TCRs) and are used in various applications, primarily in the field of immunotherapy and vaccine development.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell binding fusion peptides.

Key players in T-cell binding fusion peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to T-cell binding fusion peptides

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Immatics 305 Unlock Company Profile
Bristol-Myers Squibb 71 Unlock Company Profile
Fate Therapeutics 69 Unlock Company Profile
CARsgen Therapeutics 59 Unlock Company Profile
Cellectis 49 Unlock Company Profile
Precision Biosciences 44 Unlock Company Profile
EXUMA Biotech 43 Unlock Company Profile
CRISPR Therapeutics 43 Unlock Company Profile
Novartis 40 Unlock Company Profile
Editas Medicine 34 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 32 Unlock Company Profile
Intellia Therapeutics 29 Unlock Company Profile
bluebird bio 25 Unlock Company Profile
NantWorks 17 Unlock Company Profile
F. Hoffmann-La Roche 15 Unlock Company Profile
Gilead Sciences 12 Unlock Company Profile
IO Biosciences 11 Unlock Company Profile
Sangamo Therapeutics 11 Unlock Company Profile
Etubics 10 Unlock Company Profile
DRK-Blutspendedienst Baden-Wurttemberg-Hessen 10 Unlock Company Profile
Sorrento Therapeutics 8 Unlock Company Profile
Fujifilm 8 Unlock Company Profile
Bayer 6 Unlock Company Profile
Abcyte Therapeutics 5 Unlock Company Profile
2Seventy Bio 5 Unlock Company Profile
Georg-Speyer-Haus 5 Unlock Company Profile
Fortress Biotech 5 Unlock Company Profile
Cartherics 4 Unlock Company Profile
Shanghai Cell Therapy Group 4 Unlock Company Profile
Autolus 4 Unlock Company Profile
Asclepius Technology Group Suzhou 4 Unlock Company Profile
ProvIncial Health Services Authority 4 Unlock Company Profile
General Hospital 4 Unlock Company Profile
KSQ Therapeutics 3 Unlock Company Profile
F1 Oncology Sezc 2 Unlock Company Profile
Shanghai Yijie Biotechnology 2 Unlock Company Profile
Obsidian Therapeutics 2 Unlock Company Profile
CBMG 2 Unlock Company Profile
Innovative Cellular Therapeutics 2 Unlock Company Profile
NEW HOPE, CITY OF 2 Unlock Company Profile
Humanigen 2 Unlock Company Profile
Noile-Immune Biotech 1 Unlock Company Profile
TCR2 Therapeutics 1 Unlock Company Profile
Aleta Biotherapeutics 1 Unlock Company Profile
NeoImmuneTech 1 Unlock Company Profile
A2 Biotherapeutics 1 Unlock Company Profile
Poseida Therapeutics 1 Unlock Company Profile
Huadong Medicine 1 Unlock Company Profile
BioAtla 1 Unlock Company Profile
Nationwide Children's Hospital 1 Unlock Company Profile

Source: GlobalData Patent Analytics

Immatics is one of the leading patent filers in T-cell binding fusion peptides. Immatics is a clinical-stage biopharmaceutical company that specializes in the development of innovative immunotherapies for the treatment of cancer. The company's focus is on harnessing the power of the immune system, particularly T cells, to target and eliminate cancer cells. Immatics is known for its focus on T-cell receptor (TCR) therapies, cancer vaccines, and other immunotherapeutic approaches. Bristol-Myers Squibb (BMS) and Fate Therapeutics are some of the other key patent filers in T-cell binding fusion peptides.

In terms of application diversity, Fujifilm leads the pack, while Provincial Health Services Authority and Autolus stood in second and third positions, respectively. By means of geographic reach, Immatics held the top position followed by F. Hoffmann-La Roche and Precision Biosciences.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.